Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692016 · ClinicalTrials.gov registry record · Phase 1
Fast & Fed Pharmacokinetic (PK) Study
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00692016 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 32 participants.
The verdict
NCT00692016, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to provide information on how well an extended release formulation (a medication that is released and absorbed over a longer period of time than a regular release formulation of the medication) of naproxen sodium is absorbed into the bloodstream after eating a high calorie breakfast and also after fasting (not eating for 14 hours).
Interventions
- DRUG Naproxen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692016
The ClinicalTrials.gov registry entry for NCT00692016 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naproxen sodium is the first listed.
NCT00692016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00692016 about?
NCT00692016 is a clinical study titled "Fast & Fed Pharmacokinetic (PK) Study". The purpose of this study is to provide information on how well an extended release formulation (a medication that is released and absorbed over a longer period of time than a regular release formulation of the medication) of naproxen sodium is absorbed into the bloodstream after eating a high calor...
What is the current status of trial NCT00692016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-01. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00692016?
The interventions under investigation include: Naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00692016?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.